Our Approach to Corporate Responsibility At Ionis, we work with a sense of urgency to discover, develop and deliver medicines to create a better future for people with serious diseases. We believe operating responsibly and sustainably creates long-term value for our company and our stakeholders. Every day we work to create a positive impact for […]
Olezarsen met the primary endpoint with a statistically significant reduction in triglyceride levels versus placebo First study to show an absolute reduction in acute pancreatitis in FCS patients, with olezarsen 80 mg monthly dose reducing events by 100 percent Olezarsen demonstrated a favorable
Overview As a part of our commitment to discover, develop, and deliver medicines to the patients who depend on us, we believe in supporting investigator-initiated research (IIR) to advance medical and scientific knowledge in our research areas of interest. We define IIR as unsolicited research conceived, initiated, and conducted independently of Ionis. An external investigator […]
Mr. Klein has served as a director of Ionis since December 2005. Mr. Klein is currently managing director of Gauss Capital Advisors, LLC, a financial consulting and investment advisory firm focused on biopharmaceuticals, which he founded in March 1998. From September 2003 to December 2008, Mr. Klein also served as a venture partner of Red […]